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Abstract
Alzheimer’s disease (AD) is the most common form of dementia in the elderly with progressive cognitive decline and
memory loss. According to the amyloid-hypothesis, AD is caused by generation and subsequent cerebral deposition of b-
amyloid (Ab). Ab is generated through sequential cleavage of the transmembrane Amyloid-Precursor-Protein (APP) by two
endoproteinases termed beta- and gamma-secretase. Increased APP-expression caused by APP gene dosage effects is a risk
factor for the development of AD. Here we carried out a large scale screen for novel compounds aimed at decreasing APP-
expression. For this we developed a screening system employing a cell culture model of AD. A total of 10,000 substances
selected for their ability of drug-likeness and chemical diversity were tested for their potential to decrease APP-expression
resulting in reduced Ab-levels. Positive compounds were further evaluated for their effect at lower concentrations, absence
of cytotoxicity and specificity. The six most promising compounds were characterized and structure function relationships
were established. The novel compounds presented here provide valuable information for the development of causal
therapies for AD.
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Introduction
Alzheimer’s disease (AD) is the most common neurodegener-
ative disease [1]. Symptoms include cognitive dysfunction,
behavioral disturbances and difficulties with performing activities
of daily living [2]. Probable AD is diagnosed by presence of
characteristic neurological and neuropsychological features and
auxiliary tests such as neuroimaging and cerebrospinal fluid
analyses, but the definite diagnosis of AD can only be made
postmortem. The neuropathological hallmarks of the disease
include brain atrophy, the presence of intracellular neurofibrillary
tangles consisting of hyperphosphorylated tau-protein and extra-
cellular deposition of b-amyloid (Ab) [3].
Ab is generated by post-translational processing of the Amyloid-
Precursor-Protein (APP), a transmembrane protein, implicated in
synapse formation [4] and trophic support [5]. There are two
cleavage pathways of APP, a nonamyloidogenic and an amyloido-
genic pathway [6]. Nonamyloidogenic cleavage of APP, by a-
secretase and the c-secretase complex releases an APP intracellular
domain (AICD), the 23–25 amino-acid long p3 fragment and
soluble APP (saAPP). Amyloidogenic cleavage of APP by b-site
APP cleaving enzyme 1 (BACE1) and the c-secretase complex
generates Ab-alloforms ranging from 38 to 43 (Ab38–Ab43) amino
acid length [7]. The main alloforms of Ab in amyloid deposits are
40 (Ab40) and 42 (Ab42) acids long. Besides this, a soluble N-
terminal APP fragment (sAPPb) and AICD is produced. Accord-
ing to the amyloid hypothesis, generation and tissue deposition of
Ab is causal for neurodegeneration with Ab42 aggregating readily
and possessing high neurotoxicity [8]. Current hypothesis to
explain Ab-induced neurodegeneration include direct toxicity via
the mitochondrial apoptotic pathway [9] or through activation of
caspases [10],[11] and receptor mediated toxicity involving the N-
methyl-D-aspartate receptor (NMDAR) [12].
The majority of AD cases are sporadic and show an association
to the apolipoprotein E (APOE) e4 allele as a genetic risk factor
[13],[14]. Familial AD (FAD) is an autosomal dominant disorder
with early disease onset. FAD is associated with mutations in
presenilin-1 (PS1), presenilin-2 (PS2) or APP genes [15],[16],[17].
Recently copy number variations of APP have been shown to be
causative for AD [18],[19]. The importance of APP gene dosage
effects for the development of AD has been studied extensively in
trisomy 21 patients where triplication of chromosome 21 including
the APP-gene locus invariably leads to early-onset AD
[20],[21],[22],[23].
Presently, there are no validated and licensed Ab-lowering
therapeutics. Efforts to develop drugs which specifically target
BACE1 or the c-secretase complex are complicated due to the
pleotropic effects of these proteases leading to dramatic side effects
[24],[25],[26],[27].
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Moderate decrease of APP expression seems to be an attractive
target for AD therapy. Therefore we screened for APP-lowering
compounds using a newly developed, cell-based screening method.
Of 10,000 high diversity, quality drug-like and lead-like com-
pounds, we identified five which were non-cytotoxic, were effective
at lower concentrations and lead to a selective reduction of APP
and its cleavage product Ab. Our data opens a new therapeutic
approach by targeting APP and may lead to development of novel
drugs to treat AD.
Materials and Methods
Cell culture
Human embryonic kidney 293 (HEK) cells [28] were grown in
Dulbecco’s modified Eagle’s medium high glucose with L-
glutamine, supplemented with 10% fetal bovine serum, 1%
penicillin/streptomycin (PAA Laboratories, Paching, Austria) in
a 5% CO2 incubator. The APPsw cells (gift from C.Haass), are
stably transfected HEK cells overexpressing APP with a double
mutation at codons 670/671 and 5–8 fold increase in Ab
production when compared to wild type HEK-cells [29]. They
were grown as described above with supplemental 1% Gentamy-
cin (G418; PAA Laboratories). N2a cells (mouse neuroblastoma
cell line) were grown as described above without G418. N2a cells
were stably transfected with APPsw using the FUGENEHHD
transfection kit, cells were grown with G418. APPsw or N2asw
cells were plated on 96-well plates (100 ml/well = 30.000 cells/
well). After 1 day, compounds (one compound/well) were added to
media, untreated controls received solvent only. Initial concen-
trations were 100 mM (in 1% Dimethyl sulfoxide (DMSO)) [30].
To check effects at lower concentrations, compounds were used at
concentrations of 100 mM, 50 mM, 10 mM and 1 mM. Superna-
tants (for Dot blot, Western blot and ELISA) or cells (for Western
blot and quantitative reverse transcription PCR) were collected
after 3 days of incubation.
Immunofluorescence
To assess transfection-efficiency, cells were grown on cover slips,
fixed in acetone (20 min at 220uC), rinsed with phosphate-
buffered saline, pH 7.4 (PBS, PAA Laboratories) and blocked with
5% donkey serum (Dianova, Hamburg, Germany). As primary
antibody, anti-APP/Ab antibody 6E10 recognizing the first 16
amino acids of Ab was used (1:200, Covance, Princeton, USA).
After washing with PBS the secondary antibody (1:500, Alexa-
Fluor 488-labled donkey anti-mouse, Invitrogen, Carlsbad, USA)
and 496-Diamidino-29-phenylindole (DAPI, 1:200 Roche, Mu-
nich, Germany) were added, coverslips were embedded in
Fluoromont G (Biozol, Munich, Germany) and analyzed by
fluorescence microscopy (Leica Laser Scanner Confocal Micro-
scope TCS SP2 (Leica, Wetzlar, Germany)).
Compound library
The compound library DIVERSetTM (Chembridge, San Diego,
USA) consists of 10,000 substances supplied in 125 96-well-plates
with 80 compounds each at a concentration of 2 mmol, solved in
200 ml DMSO. Due to their structural characteristics all
substances are predicted to fulfil the Lipinski’s rule of five for
drug-likeness. For detailed information (including structural data)
see: www.chembridge.com.
Dot blot analysis
Dot blots to assess soluble a-APP were performed as published
[31]. Briefly, polyvinylidene difluoride (PVDF) membrane (Biorad,
Munich, Germany) was rinsed in 10 ml of methanol for 3 sec,
equilibrated in PBS for 1 min, and placed in a dot blot apparatus
(TE70 ECL Semi-Dry Transfer Unit, Amersham Biosciences,
Freiburg, Germany). The supernatant of each well was spotted
with an Eppendorf Multipipette onto the PVDF membrane
through the sample wells of the Dot blot apparatus to obtain
reproducible 3-mm-diameter dots in the pattern of a 96-well
microtiter plate. Proteins were blotted on the membrane by
negative pressure using a vacuum pump. The membrane was
dried at 37u for 1 h, blocked in 5% (w/v) fat-free milk powder in
PBS (PAA Laboratories), and incubated with the 6E10 antibody
(1:10,000, 4uC over night, Covance). After washing with PBST
(PBS containing 0.1% Tween-20), secondary anti-mouse antibody
(Promega, Fitchburg, USA) was used at a dilution of 1:10,000.
Blots were developed with ECL enhanced chemiluminescence
(Sigma) in an Imager Gel Doc System (Biorad).
Toxicity tests
To assess proliferation and cell viability, compound-treated cells
were subject to MTT and Trypan Blue assays. MTT-Assay
(CellTiter 96H Proliferation Assay, Promega) was performed as
recommended by provider and absorbance was measured by
mQuant spectrophotometer at OD570 (Biotek, Winooski, USA).
Trypan Blue Stain 0,4% (Invitrogen) was performed as published
[32] and percentages of surviving cells were calculated by using a
Neubauer counting chamber.
Western blot
For Western blot analysis of supernatants, 100 ml of media was
centrifuged and supernatants were boiled with loading buffer and
run on 8% SDS-PAGE, blotted and probed 6E10 (1:1000,
Covance), 3F4 (1:100, Covance) and rabbit monoclonal b-actin
antibody (1:5000, Sigma), as well as matching secondary
antibodies (1:5000, Promega). For cell lysates procedures were
identical but 200 mg of homogenate in RIPA buffer was used. For
visualisation and quantification ECL enhanced chemilumines-
cence (Sigma), Imager Gel Doc System and Quantity One
Software (Biorad) was used. For determination of glycosylation
ratios between mature and immature APP, band intensities were
compared and expressed as ratios.
Real-time RT-PCR
The RNA was isolated from cell lines using the RNA Miniprep
Kit (Stratagen, Basel, Switzerland). The purification of RNA was
carried out with RNeasy Lipid Tissue Mini Kit (Qiagen, DE)
following the protocol provided by the manufacturer. During
purification, samples were treated with RNase-free DNase Set
(Qiagen, DE) to avoid later amplification of genomic DNA. The
concentration of each sample was obtained from A260 measure-
ments with Nanodrop 1000. RNA integrity was tested using the
Agilent 2100 BioAnalyzer (Agilent, US).
ELISA
For quantification of Ab40 and Ab42 we used Ab40/Ab42-
specific sandwich Enzyme Linked-Immuno-Sorbent Assay accord-
ing to manufacturer’s instructions. Briefly, media were centrifuged
at 1000 rpm for 5 min (at 4uC), supernatants (50 ml) were added to
antibody-coated wells, capture antibody was added and extinction
was measured at 450 nm by spectrophotometer (mQuant, BioTek).
Statistical analysis
In all experiments, means +/2 SD are reported. Statistical
comparisons among groups were determined using Student’s t-test
APP Lowering Small Molecules
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with statistical significance at p-values,0.05 (*), ,0.01 (**) and
,0.001 (***).
Identification of similar structures
To assess novelty and to identify similar activities a number of
prominent databases were accessed. These included ChEMBL
[33], ChemSpider [34], BindingBD [35], PubChem [36], Drug
Bank [37], Espacenet [38] and Google Scholar [39] and were
accessed between 29th May 2013 and 25th June 2013.
Results
A cell-based AD model
As a cell culture model for AD we used HEK cells stably
transfected with human APP harboring the Swedish mutation
(APPsw). Expression of APP and Ab was assessed by immunohis-
tochemistry for APP/Ab using the 6E10 antibody. This revealed
strong expression of APP/Ab on plasma membrane as well as
intracellularly in nearly 100% of cells (Fig. 1A). Since compounds
used for our screen were dissolved in DMSO we excluded
unspecific effects of DMSO on expression of APP and generation
of Ab by exposing cells to ascending concentration of DMSO
added to the media. There were no significant differences
regarding APP expression or generation of Ab up to a 1/100
dilution of DMSO in media (data not shown).
Screen for APP-lowering small molecules
The goal of this study was to identify compounds reducing
expression of APP. Thus our initial screen using a compound
library (ChemBridge DIVERSetTM) with 10,000 small molecules
designed for high chemical diversity and drug-likeness focused on
identifying compounds that decrease the amount of saAPP in the
supernatant.
For this, cells were incubated for 72 hours with above
mentioned compounds and supernatants were analyzed by dot
blot using the monoclonal antibody 6E10 recognizing saAPP. The
validity of our approach is shown in Fig. 1B where strong uniform
signal for saAPP is only observed in APPsw but not in control
HEK cells. For the initial screen, compounds were added at a
concentration of 100 mM to single wells in a 96-well format
allowing for the simultaneous assessment of 80 compounds
(Fig. 1C). Only compounds showing strong saAPP reduction in
four independent experiments were evaluated as ‘‘positive’’, thus
eligible for further investigation. Of 10,000 compounds, 223 were
‘‘positive’’ and were assessed for effectiveness at lower concentra-
tions by incubating cells for 72 hours with compounds at
concentrations of 100 mM, 50 mM, 10 mM and 1 mM. As above,
supernatants were analyzed by dot blot and compounds were
evaluated as ‘‘positive’’ when effects were seen at lower
concentrations in four independent experiments. Sixteen com-
pounds were effective at 10 mM and two compounds showed a
significant reduction of saAPP at 1 mM. In order to exclude
unspecific effects on cell viability or cellular metabolism, we
assessed cytotoxicity of compounds by Trypan Blue assay and
influence on proliferation of compounds by MTT-assay. Of the
sixteen compounds showing reduction of saAPP at lower
concentrations, six did not show effects on proliferation and were
non-cytotoxic (Fig. 2A). Two compounds which decreased saAPP
signal up to 1 mM (Compound B and C) and four compounds that
decreased saAPP signal up to 10 mM (Compound A, D–F) were
chosen for further analysis (Fig. 2B). Cytotoxic compounds or
compounds with effects only at 100 mM and 50 mM were excluded
Fig. S1A, B, C).
Reduction of full-length intracellular/plasma membrane bound
APP and saAPP was confirmed by Western Blot analyses of cell
lysates and supernatants 72 hours after incubation with the six
selected compounds (at 10 mM). In this analysis, all of the six
compounds led to a significant reduction of intracellular/plasma
membrane bound APP and saAPP (Fig. 3A, n= 5, p***,0.001).
To determine if reduction of full-length intracellular/plasma
membrane bound APP and saAPP also applies for neuronal cells,
we treated stably transfected neuronal N2asw cells with the six
selected compounds (10 mM, 72 hours) and performed Western
Blots of cell supernatants and cell lysates. We could not observe
cytotoxic effects for these compounds when assessed by MTT-
assay (Fig. S2A, n= 3, **p,0.01). Amounts of intracellular/
plasma membrane bound APP and saAPP were decreased for all
six compounds (Fig. S2B, n= 2).
Reduction of Ab40 and Ab42 by saAPP-lowering
compounds
To confirm that selected compounds reduce the amount of Ab40
and Ab42 we analyzed supernatants following three-day com-
pound treatment by Ab40 and Ab42 specific ELISA. HEK cells
produce small amounts of Ab40, whereas Ab42-production is under
the detection limit, whereas APPsw cells produce large amounts of
Ab40 and lower amounts of Ab42. All six tested compounds
significantly reduced amounts of Ab40 and Ab42 with relative
reductions ranging from 36%–59% for Ab40 and 21%–56% for
Ab42 (Fig. 3B, C, n= 3, **p,0.01; ***p,0.001).
Specificity of saAPP-lowering compounds
To exclude nonspecific reduction of neuronal membrane
proteins we assessed expression of PrPC as membrane-bound,
highly abundant neuronal protein. PrPC represents a good control
protein since it localizes to similar membrane microdomains and
its expression is not regulated by APP [40]. With the exception of
compound B there was no significant regulation of PrPC by tested
compounds (Fig. S3).
Transcriptional and posttranslational effects of saAPP-
lowering compounds
In order to investigate if decrease of saAPP is due to
transcriptional regulation we determined mRNA levels of APP
using quantitative RT-PCR using established methods [41]. For
compound B we observed transcriptional effects on APP mRNA
levels 72 hours after compound treatment whereas for compounds
A, C, D, E and F no transcriptional effects were observed (Fig. 3D,
n= 2).
APP is N-glycosylated in the ER and cis-Golgi followed by O-
glycosylation in medial- and trans-Golgi [42]. The mature form of
APP is fully glycosylated (mAPP) whereas the immature form is N-
glycosylated (imAPP) [43]. mAPP undergoes cleavage by b- and c-
secretases in the secretory pathway or at the plasma membrane
whereas imAPP locates to endoplasmic reticulum or cis-Golgi and
is not subject to cleavage [44]. To investigate if this posttransla-
tional modification is changed upon treatment with compounds,
we calculated the ratio between mature and immature APP 3 days
after of incubation with compounds at 10 mM. All of the tested
compounds with the exception of compound A led to a shift of
glycosylation pattern towards predominantly immature APP when
compared to controls where the ratio between mAPP and imAPP
is balanced (Fig. S4, n = 3, *p,0.05).
APP Lowering Small Molecules
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Identification of similar structures
We identified 6 compounds out of the 10,000 which decreased
the amount of APP or Ab at lower concentrations (10 mM) and
which were not cytotoxic (Fig. 4A). These findings could be used as
starting points for further investigations in developing therapeutic
targets. All structures of the 6 compounds are presented in
figure 4B. We performed structural comparisons to determine
promising structures of the molecules (Fig. S5). The activities and
the predicted physicochemical properties of these structures (e.g.
cLogP), which are well within the ‘lead-like’ and ‘Drug-like’ space,
make them very interesting starting points for Drug Discovery
efforts. Two of these six structures, compounds A and D contain a
5-bromonicotinamide moiety. Within the screening set, there were
other compounds with this moiety that showed reduced or no
activity, indicating some SAR. Thus compounds M and N were
weakly active at 100 uM, whilst O and P were inactive at this dose.
Compound A has been widely screened within the NIH Molecular
Libraries initiative and has only proved active nine times out of the
five hundred and ninety one assays in which it has been screened,
indicating that it is not a promiscuous structure. None of the assays
run are similar to the one of this report. Compound A does appear
in a patent containing diverse structures as ‘Ganglioside Biosyn-
thesis Modulators’ [45]. This could be a mode of action by
increasing the immature form of APP, even if there is no shift in
the mature/immature APP ratio in our Western Blots, but further
work would need to be done to confirm this. There is also some
SAR around compound C within the 10,000 compounds
screened. Compound Q shows weak activity at 100 uM whilst a
compound that is very closely related to C, compound R, is
inactive. Compound C has also been widely screened within the
NIH Molecular Libraries programme and of the 652 assays run, it
was only active in 10 – all of these were CYP450 assays. This
cytochrome activity is unsurprising for a molecule with an exposed
pyridine nitrogen atom and is not likely to be directly related to the
activity of this current report. There is also some additional data
from this screen for compound B, with compounds S and T both
active without toxicity at 50 uM. This structural class has
previously been reported to prevent Huntingtin protein aggrega-
tion which may have some relevance [46]. However, with the
potentially nonspecific effects seen with B, interest in this
compound/series is perhaps lower than the others. Few analogues
of compound E were assayed, although compound U was inactive
Figure 1. Characterization of a new cell-based assay for screening of APP-lowering small molecules. A) Expression of APP/Ab in APPsw
transfected HEK 293 cells and in HEK 293 cells. APPsw cells and HEK cells were fixed, labelled with 6E10 antibody and stained with Cy3 anti-mouse IgG
for detection of APP/Ab (red). Nuclei were stained with DAPI (blue). Scale bar 25 mm. B) Supernatants of HEK and APPsw cells were characterized via
dot blot with the 6E10 antibody. APPsw cells produce a higher level of saAPP than control HEK cells. C) Representative example of a dot blots from
the screening stage of the study. Supernatants of compound-treated APPsw cells and controls (solvent-treated APPsw, extreme left and right lane).
With this approach 80 compounds could be assessed in parallel. Only compounds reducing the signal in four independent experiments were
evaluated as ‘‘positive’’.
doi:10.1371/journal.pone.0082255.g001
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Figure 2. Identification of six compounds lowering APP levels at lower concentrations are non cytotoxic. A) Toxicity assays. Trypan Blue
Assay was performed after 3 days of compound incubation. The percentage of surviving cells was calculated. 1%DMSO was used as a negative and
10% DMSO as a positive control. For the MTT assay absorbance of formazan was measured at 570 nm. All experiments were performed in triplets.
APP Lowering Small Molecules
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at 100 uM suggesting that pyridyl moiety is important for activity.
Further investigation in this area of the molecule would also seem
sensible, including CYP450 binding. There is again a hint of SAR
around compound F - from the small set of related compounds
screened, the data suggests that activity may require the
benzimidazole and a second basic centre – compound V is
inactive at 100 uM whereas compounds W and X show weak
activity at this concentration.
Discussion
We have established a novel cell-based method to screen for
compounds lowering APP. Using this approach we have
indentified six promising compounds out of 10,000 which
significantly reduce levels of APP, Ab40 and Ab42 at lower
concentrations, are non-cytotoxic, do not change the metabolic
activity and fulfill the terms fur drug-likeness, which is a key fact
for developing AD drugs. APP-lowering effects could be seen in
non-neuronal HEK cells and in neuronal N2a cells.
There are several possibilities how these compounds interfere
with Ab generation. One possibility is transcriptional downregu-
lation of APP mRNA. APPsw cells mainly express APP 695 which
is the APP isoform with the highest propensity to be processed to
Ab [47]. The transcription of APP can be affected by negatively
influencing transcription factors or regulatory sequences in
promoter regions of APP [48],[49],[50]. Compound B reduces
APP mRNA levels and may function on the transcriptional level,
Results are shown as mean6S.D., n = 3, ***p,0.001. B) The effect of different concentrations was assessed using serial dilutions (100 mM, 50 mM,
10 mM, 1 mM) in four independent experiments. Untransfected HEK 293 cells and solvent-treated APPsw cells were used as controls. A representative
example (n = 4) of one blot of the 6 non-cytotoxic compounds is shown.
doi:10.1371/journal.pone.0082255.g002
Figure 3. Assessment of APP, Ab40 and Ab42 levels in compounds-treated APPsw cells. A) Western blot of the cell lysates and the
supernatants of APPsw cells after 3 day incubation with compounds (10 mM). Arrows indicate fully glycosylated mature, incompletely glycosylated
immature APP and saAPP. b-actin serves as loading control. First Graph showing relative expression of mAPP and imAPP normalized to expression of
actin, untreated APPsw controls were set to 1. Results are shown as mean6S.D., n = 5, ***p,0.001. Second Graph showing relative expression of
saAPP normalized to expression of actin, untreated APPsw controls were set to 1. Results are shown as mean6S.D., n = 5, ***p,0.001. B) Ab40
quantification by ELISA with the supernatant of APPsw cells after 3 days of compound incubation (10 mM). Ab40 and Ab42 levels were decreased
significantly. Untreated APPsw cells and HEK cells are used as controls. Data are the mean 6 S.D., n = 3, **p,0.01, ***p,0.001. C) Ab42 quantification
by ELISA with the supernatant of APPsw cells after 3 days of compound incubation (10 mM). Ab40 and Ab42 levels were decreased significantly.
Untreated APPsw cells and HEK cells are used as controls. Data are the mean 6 S.D., n = 3, **p,0.01, ***p,0.001. D) mRNA levels of APP were
measured by RT-PCR in treated APPsw cells and HEK cells, untreated APPsw cells were set to 1. Compound B reduces the amount of APP-mRNA. Data
are the mean of two experiments.
doi:10.1371/journal.pone.0082255.g003
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Figure 4. Characterization of the six best compounds. A) Flowchart of the screening of the 10,000 compound library DIVER Set. 10,000
compounds were screened and hits were analyzed by serial dilutions (100 mM, 50 mM, 10 mM, 1 mM). Compounds effective at lower concentrations
were checked for cytotoxicity and the non-cytotoxic ones were further analyzed by western blot, ELISA and RT-PCR. B) Structures of the highly potent
5 compounds (A, C–F) in the DIVER Set library which have an specific effect on APP/Ab-production at a concentration of a minimum of 10 mM and are
not cytotoxic. The structure of compound B is added below.
doi:10.1371/journal.pone.0082255.g004
APP Lowering Small Molecules
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although this relative reduction is influenced by stable overex-
pression of APPsw in our cell culture model. Since this compound
also decreased levels of PrPC these actions may be due to
unspecific effects making this compound the least attractive
compound identified by us.
Another way of interfering with Ab generation is by influencing
the trafficking and proteolytic processing of APP [51],[52]. Once
APP reaches the plasma membrane, it is rapidly internalized and
subsequently trafficked through endocytic and recycling compart-
ments back to the cell surface or degraded in the lysosome [43].
Disturbed trafficking to the plasma membrane or enhanced
degradation in lysosomes, could explain reduced levels of
intracellular/plasma membrane APP. A second possibility could
be the inhibition of APP maturation by modification of the Golgi
apparatus. Recently it could be shown that X11-llike, a neural
adaptor protein, regulates intracellular trafficking of APP by this
process [44]. O-glycosylation is a prerequisite for c-secretase
cleavage [53], therefore interference with O-glycosylation may
result in decreased Ab production. Although we did not investigate
this in detail, for compounds B–F we observed a shift to the
immature form of APP.
Finally the sequential cleavage of APP by a-, b- and c-secretases
represents a putative target. Since we designed our compound
screen looking at reductions of saAPP, which nicely correlates with
APP-levels, direct influence of our compounds on a-, b- and c-
secretases activity is unlikely.
Recently published studies identified lead compounds aimed at
treating a wide range of conformational dementias based on their
potential to inhibit protein aggregation [54],[31]. Our approach
differs from this approach as we screened for compounds aimed at
reducing the substrate subject to dementia causing misprocessing.
Combining both approaches represents an attractive strategy to
indentify highly potent compounds to treat dementia where
protein aggregation is causally involved.
In conclusion, we have indentified six compounds which reduce
the amount of Ab40 and Ab42 possibly by influencing APP
expression (for instance compound B) or APP maturation
(compound C, D, E, F). APP-lowering effects could be seen in
non-neuronal and neuronal cells.
All compounds with the exception of compound B did not affect
expression of other membrane bound neuronal proteins such as
PrPC. From a Medicinal Chemistry point of view, each of the
screening hits constitutes an interesting starting point for Drug
Discovery in this vitally important disease area. All of the
compounds have excellent potency for lowering APP and
predicted analogues may show enhanced profiles.
Future studies will focus on the in vivo relevance, optimization of
lead structures and on assessing if these compounds have potential
for treating other dementias.
Supporting Information
Figure S1 Some compounds reducing APP at lower
concentrations are cytotoxic. A) Effect at lower concentra-
tions was assessed using serial dilutions (100 mM, 50 mM, 10 mM,
1 mM) in four independent experiments. Untreated APPsw cells
were used as controls. One example of a blot is presented.
Compound G, H, J, K, L reduce the APP level in a dose of 50 mM
like 33 other compounds. B) I is one of the 10 compounds, which
reduce the APP level at 10 mM, but are cytotoxic. Results are
shown as mean6S.D., n= 3, ***p,0.001. C) Structures of some
compounds (G–L) which were cytotoxic or reduce the APPsw level
only at a dose of 50 mM.
(TIF)
Figure S2 Effect of compounds on N2a cells. A) Toxicity
assays. For MTT assay absorbance of formazan was measured at
570 nm. All experiments were performed in triplets. 1%DMSO
was used as a negative and 10% DMSO as a positive control. We
exclude toxic effects on neuronal cells. Results are shown as
mean6S.D., n= 3, **p,0.01. B) Western blot of the cell lysates
and the supernatants of N2a and N2asw cells after 3 day
incubation with compounds (10 mM). Arrows indicate fully
glycosylated mature, incompletely glycosylated immature APP
and saAPP. First Graph shows relative expression of mAPP and
imAPP normalized to expression of actin, untreated N2asw were
set to 1. Results show means of two experiments. Second Graph
shows relative expression of saAPP normalized to expression of
actin, untreated N2asw were set to 1. Results show means of two
experiments.
(TIF)
Figure S3 Assessment of specificity. Western Blot of cells
lysates and supernatants of APPsw cells after 3 day incubation with
compounds (10 mM). Arrow indicates PrPC (diglycosylated,
monoglycosylated and unglycosylated). b-actin serves as a marker
for equal loading. Histogram showing relative expression of PrPC
normalized to expression of actin, untreated APPsw controls were
set to 1. Results are shown as mean6S.D., n= 3, *p,0.05.
(TIF)
Figure S4 Effect of compounds on APP-glycosylation. Analysis
of Glycosylation ratio. The ratio of mature to immature APP was
calculated. Compound B, C, D, E and F lead to a shift to
immature APP. Results are shown as mean6S.D., n= 3, *p,0.05.
(TIF)
Figure S5 Structural comparison. We checked similarity to
other compounds of the library (compound M–X) and their
appearance in other databases to determine promising structures
of the molecules.
(TIF)
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